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Introduction

erythroid and myeloid precursors along with plentiful
megakaryocytes suggesting immune mediated destruction of
platelets. There was clearance of the disease. She was started on
Prednisolone 30mg PO bid, but the symptoms persisted with the
platelet counts remaining less than 10,000/cumm. She received a
course of intravenous immunoglobulin 1gm/kg for two days. Her
symptoms improved and the platelet counts gradually increased.
Platelets counts stabilized to more than 150,000/cumm in six
weeks time.

Fludarabine is a purine nucleoside analogue, which inhibits
DNA synthesis by inhibiting DNA polymerase and ribonucleoside
reductase.1 It affects both dividing and non- dividing cells.2
Fludarabine possesses proven efficacy in the treatment of a variety of
indolent B cell lymphoproliferative disorders including chronic lymphocytic leukemia3, low-grade non-Hodgkin's lymphoma4 and
Waldenstrom macroglobulinemia.5 It is also a part of conditioning
regimes in non-myeloablative bone marrow transplantation.6 The
common side effects include myelosuppression, immunosuppression,
Discussion
and neurologic toxicity.7 The rare side effects are immune mediated
Patients with lymphoproliferative disorders have an
hemolytic anemia8 and thrombocytopenia.9 Here we describe a case of
increased risk of autoimmune disorders such as autoimmune
a middle-aged lady who was diagnosed as B cell chronic lymphocythemolytic anemia and thrombocytopenia.10,11 Pathogenesis is
ic leukemia and developed immune mediated thrombocytopenia folobscure, however it has been postulated that leukemic B cells
lowing oral Fludarabine.
elaborate immune suppressive cytokines, such as transforming
growth factor beta, which may account for the reversal in the ratio
Case Report
of CD4 to CD8 T cells.12 There is also a down regulatory expresFifty years old female presented to the hematology outpatient sion of CD154 (CD40-ligand), a surface glycoprotien that is
with a history of low-grade fever, weight loss and painless swellings expressed on CD4 + T cells following immune activation.
on both sides of neck since one month. She was a known patient of Because CD154 (CD40-ligand) plays a critical role in the develdiabetes mellitus and hypertension. There was no previous history of opment of an immune response, such down modulation may be
autoimmune diseases. Examination at the time of presentation responsible for an immune deficiency state.13,14 Fludarabine is a
revealed bilateral cervical and axillary lymphadenopathy. Spleen was potent suppressor of T lymphocytes and this drug may accelerate
palpable 3cm below the left subcostal margin. Rest of the general and the pre existing T cell immune suppression that normally occur
systemic examination was unremarkable. Investigations revealed during progression of chronic lymphocytic leukemia, exacerbathemoglobin 12.1 gm/dl, white cells count 35,500/cumm and platelets ing the underlying tendency to autoimmunity.11 The pathogenic
277,000/cumm. Absolute lymphocyte count was 28,000/cumm. Bone autoantibodies generally do not appear to be produced by the
marrow and bone trephine findings were consistent with the diagnosis
malignant B cell clone.15
of lymphoproliferative disorder (chronic lymphocytic leukemia).
This patient developed immune mediated thrombocytopeImmuno-phenotyping revealed positivity against CD5, CD19, CD20
nia
after
four courses of Fludarabine and recovered completely in
and CD22 and hence consistent with B cell chronic lymphocytic
six
weeks
time. As it has been observed that these patients usualleukemia. Other laboratory investigations were within normal ranges.
ly
recover
within ten weeks9 so the option of splenectomy should
Serial blood counts subsequently revealed progressive increase in
absolute lymphocyte count along with an increase in the percentage of be reserved for those patients who are refractory to first line therprolymphocytes. On physical examination, there was an increase in apy with persistent significant thrombocytopenia for more than
ten weeks. Re-exposure to the drug can lead to recurrent thrombothe number and size of lymph nodes of cervical region.
cytopenia9, so it is advisable not to rechallenge the patient who
Initially she received three cycles of tablet chlorambucil 10mg
has had an episode of immune mediated thrombocytopenia.
PO daily for two weeks in a cycle of four weeks with no improvement.
She was started on tablet Fludarabine 25mg per meter square for five
days every four weeks. She responded well to the treatment. After
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